Paul Lyne
11Patents
4h-index
25Co-inventors
56Inventor score
Filing activity: Apr 12, 2002 → Mar 27, 2017
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7358054B2 | Antibodies to VLA-1 | Emerging Cross-Sectional Technologies | 30 | Expired |
| US7910099B2 | Antibodies to VLA-1 | Emerging Cross-Sectional Technologies | 9 | Active |
| US7723073B2 | Antibodies to VLA-1 | Emerging Cross-Sectional Technologies | 7 | Active |
| US8084028B2 | Antibodies to VLA-1 | Emerging Cross-Sectional Technologies | 6 | Active |
| US7429644B2 | Humanized anti-LT-β-R antibodies | Chemistry; Metallurgy | 4 | Expired |
| US7691865B2 | Pyrazolopyridines and methods of making and using the same | Chemistry; Metallurgy | 2 | Expired |
| US7423061B2 | Substitute thiophenes and uses thereof | Chemistry; Metallurgy | 0 | Expired |
| US10336826B2 | Antibodies to VLA-1 | Emerging Cross-Sectional Technologies | 0 | Active |
| US9644030B2 | Antibodies to VLA-1 | Emerging Cross-Sectional Technologies | 0 | Active |
| US8835465B2 | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | Chemistry; Metallurgy | 0 | Active |
| US8324252B2 | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.